Stephens Begins Coverage on Immunome (NASDAQ:IMNM)

Analysts at Stephens began coverage on shares of Immunome (NASDAQ:IMNM) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $30.00 price target on the stock. Stephens’ price target would suggest a potential upside of 139.23% from the company’s previous close.

Several other research firms have also recently issued reports on IMNM. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Friday, October 25th. Piper Sandler dropped their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has a consensus rating of “Buy” and a consensus price target of $29.17.

Immunome Price Performance

NASDAQ:IMNM opened at $12.54 on Friday. The business has a 50 day moving average of $13.43 and a 200 day moving average of $13.90. The company has a market capitalization of $753.08 million, a price-to-earnings ratio of -1.63 and a beta of 1.82. Immunome has a 1-year low of $6.93 and a 1-year high of $30.96.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The company had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. As a group, sell-side analysts anticipate that Immunome will post -1.92 EPS for the current year.

Insider Activity at Immunome

In related news, CFO Max Rosett sold 14,380 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Immunome news, CFO Max Rosett sold 14,380 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jean Jacques Bienaime purchased 7,000 shares of Immunome stock in a transaction on Friday, August 16th. The stock was bought at an average price of $13.94 per share, with a total value of $97,580.00. Following the transaction, the director now owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 8.60% of the stock is owned by company insiders.

Institutional Trading of Immunome

Institutional investors have recently made changes to their positions in the business. Lord Abbett & CO. LLC purchased a new stake in shares of Immunome during the first quarter worth about $10,994,000. Swiss National Bank bought a new position in Immunome during the first quarter valued at approximately $1,762,000. Sofinnova Investments Inc. boosted its stake in Immunome by 10.3% during the second quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock valued at $7,934,000 after buying an additional 61,284 shares during the last quarter. Cetera Investment Advisers bought a new position in Immunome during the first quarter valued at approximately $3,038,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Immunome by 113.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after buying an additional 1,194,451 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.